Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01076556 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Nov 11, 2015 | clinicaltrials |
| NCT01126502 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2015 |
| clinicaltrials |
| NCT00578045 | UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies | withdrawn | Phase 1 | 0 | University of ArkansasOTHER | 1 | Oct 26, 2015 | clinicaltrials |
| NCT00276536 | Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma(IFNa) | completed | Phase 1 | 35 | The Cleveland ClinicOTHER | 1 | Oct 14, 2015 | clinicaltrials |
| NCT01485835 | A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 8 | Emory UniversityOTHER | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00103558 | Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 31 | BiogenINDUSTRY | 1 | Oct 2, 2015 | clinicaltrials |
| NCT01735604 | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Sep 29, 2015 | clinicaltrials |
| NCT01180569 | Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Sep 25, 2015 | clinicaltrials |
| NCT00435084 | A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL | completed | Phase 1 / Phase 2 | 10 | Valerio TherapeuticsINDUSTRY | 1 | Sep 23, 2015 | clinicaltrials |
| NCT00915408 | A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma(CRD) | completed | Phase 1 / Phase 2 | 32 | King's College Hospital NHS TrustOTHER | 1 | Sep 2, 2015 | clinicaltrials |
| NCT00060632 | Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) | completed | Phase 1 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT00060645 | Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) | completed | Phase 1 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 27, 2015 | clinicaltrials |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection | terminated | Phase 1 | 72 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2015 | clinicaltrials |
| NCT01812096 | Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China(MM) | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 18, 2015 | clinicaltrials |
| NCT01658319 | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01889420 | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 1 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 31, 2015 | clinicaltrials |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | terminated | Phase 1 | 2 | Celgene CorporationINDUSTRY | 1 | Jul 28, 2015 | clinicaltrials |
| NCT00800059 | Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma(TMI-ASCT) | unknown | Phase 1 / Phase 2 | 27 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00689507 | A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib | completed | Phase 1 | 48 | Applied Molecular EvolutionINDUSTRY | 1 | Jun 29, 2015 | clinicaltrials |
| NCT02145715 | Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma(MUKsix) | unknown | Phase 1 / Phase 2 | 54 | Prof Jamie CavenaghOTHER | 1 | Jun 26, 2015 | clinicaltrials |
| NCT01217749 | Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL(PCYC-1109-CA) | completed | Phase 1 / Phase 2 | 71 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 25, 2015 | clinicaltrials |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | terminated | Phase 1 | 11 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT00990587 | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | completed | Phase 1 | 20 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01531998 | Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT02467647 | The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy(HLJDT-2016) | unknown | Phase 1 | 500 | Wuhan UniversityOTHER | 1 | Jun 10, 2015 | clinicaltrials |
| NCT00720135 | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 9 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01344876 | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies | completed | Phase 1 | 20 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT01397149 | Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG) | terminated | Phase 1 / Phase 2 | 4 | University of UlmOTHER | 2 | May 28, 2015 | clinicaltrials |
| NCT00100152 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) | terminated | Phase 1 | 50 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 27, 2015 | clinicaltrials |
| NCT00111813 | Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) | completed | Phase 1 | 34 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 21, 2015 | clinicaltrials |
| NCT00778752 | Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma | completed | Phase 1 / Phase 2 | 24 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT01149915 | Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias | completed | Phase 1 | 40 | Threshold PharmaceuticalsINDUSTRY | 1 | May 7, 2015 | clinicaltrials |
| NCT00092274 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00093314 | HuMax-CD20 in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00871663 | Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) | completed | Phase 1 | 123 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 20, 2015 | clinicaltrials |
| NCT01533194 | Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00735930 | Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2015 | clinicaltrials |
| NCT00694590 | Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 20, 2015 | clinicaltrials |
| NCT00864942 | Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)(Phase I BLR) | completed | Phase 1 | 28 | Georgetown UniversityOTHER | 1 | Mar 13, 2015 | clinicaltrials |
| NCT00972712 | Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | Emory UniversityOTHER | 2 | Mar 10, 2015 | clinicaltrials |
| NCT02353572 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT01120457 | First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers | completed | Phase 1 | 96 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00516191 | A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma(DMV) | withdrawn | Phase 1 / Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Mar 4, 2015 | clinicaltrials |
| NCT00891033 | Panobinostat/Velcade in Multiple Myeloma | terminated | Phase 1 | 12 | University of ArkansasOTHER | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00809276 | Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | completed | Phase 1 / Phase 2 | 92 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00343798 | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies | completed | Phase 1 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 11, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Nov 11, 2015source: clinicaltrials